

Privatklinik Lauterbacher Mühle am Ostersee, Iffeldorf, Germany (DS); Department of Cardiology, Klinikum der Universität München, Ludwig-Maximilians-University, Munich 80636, Germany (DS); German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Germany (DS, AK); Deutsches Herzzentrum München, Department of Cardiology, Technische Universität München, Munich 80636, Germany (AK)

- 1 Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. *Eur Heart J* 2020; published online Aug 29. <https://doi.org/10.1093/eurheartj/ehaa575>.
- 2 Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. *Eur Heart J* 2020; **41**: 407–77.
- 3 Sibbing D, Aradi D, Alexopoulos D, et al. Updated expert consensus statement on platelet function and genetic testing for guiding P2Y₁₂ receptor inhibitor treatment in percutaneous coronary intervention. *JACC Cardiovasc Interv* 2019; **12**: 1521–37.
- 4 Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. *JAMA* 2011; **305**: 1097–105.
- 5 Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy with Prasugrel) Study. *J Am Coll Cardiol* 2012; **59**: 2159–64.
- 6 Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. *Lancet* 2017; **390**: 1747–57.
- 7 Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y₁₂ inhibitors in primary PCI. *N Engl J Med* 2019; **381**: 1621–31.
- 8 Pereira NL, Farkouh ME, So D, et al. Effect of genotype-guided oral P2Y₁₂ inhibitor selection vs conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. *JAMA* 2020; **324**: 761–71.
- 9 Galli M, Benenati S, Capodanno D, et al. Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. *Lancet* 2021; **397**: 1470–83.
- 10 Roberts JD, Wells GA, Le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. *Lancet* 2012; **379**: 1705–11.
- 11 Shuldiner AR, O'Connell JR, Bliden KP, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. *JAMA* 2009; **302**: 849–57.
- 12 Sibbing D, Stegherr J, Latz W, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. *Eur Heart J* 2009; **30**: 916–22.

Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19



The use of rapid lateral flow antigen testing (LFT) for SARS-CoV-2 has been questioned^{1–3} with uncorroborated⁴ reports of poor LFT sensitivity. The debate surrounding the use of the Innova Lateral Flow SARS-CoV-2 Antigen Test in the UK risks confusing policy makers internationally and potentially stalling deployment of LFTs in other countries.⁵ As scientists and health professionals evaluating some of the world's largest pilots of LFT, we wish to challenge those interpretations and clarify the evidence on how such testing might be used to detect SARS-CoV-2 in minutes and improve COVID-19 control measures.

Testing for SARS-CoV-2 is central to COVID-19 management and has relied on quantitative reverse transcriptase polymerase chain reaction (PCR) technology. PCR seeks the genetic code of the virus from nose or throat swabs and amplifies it over 30–40 cycles, doubling each cycle, enabling even minuscule, potentially single, copies to be detected. PCR is thus a powerful clinical test, specifically when a patient is, or was recently, infected with SARS-CoV-2. Fragments of RNA can linger for weeks after infectious virus has been cleared,⁶ often in people without symptoms or known exposures.⁷

However, for public health measures, another approach is needed. Testing to help slow the spread of SARS-CoV-2 asks not whether someone has RNA in their nose from earlier infection, but whether they are infectious today. It is a net loss to the health, social, and economic wellbeing of communities if post-infectious

Published Online
February 17, 2021
[https://doi.org/10.1016/S0140-6736\(21\)00425-6](https://doi.org/10.1016/S0140-6736(21)00425-6)



individuals test positive and isolate for 10 days. In our view, current PCR testing is therefore not the appropriate gold standard for evaluating a SARS-CoV-2 public health test.

Most people infected with SARS-CoV-2 are contagious for 4–8 days.⁷ Specimens are generally not found to contain culture-positive (potentially contagious) virus beyond day 9 after the onset of symptoms, with most transmission occurring before day 5.^{7,8} This timing fits with the observed patterns of virus transmission (usually 2 days before to 5 days after symptom onset), which led public health agencies to recommend a 10-day isolation period.⁹ The short window of transmissibility contrasts with a median 22–33 days of PCR positivity (longer with severe infections and somewhat shorter among asymptomatic individuals).¹⁰ This suggests that 50–75% of the time an individual is PCR positive, they are likely to be post-infectious.^{11,12}

Once SARS-CoV-2 replication has been controlled by the immune system, RNA levels detectable by PCR on respiratory secretions fall to very low levels when individuals are much less likely to infect others.^{13–15} The remaining RNA copies can take weeks, or occasionally months,^{16,17} to clear, during which time PCR remains positive.⁷

A public health test for detecting someone who might be contagious is, by logical deduction, expected to have a sensitivity of around 30–40% versus PCR when testing a random sample of asymptomatic people in a steady-state outbreak.¹⁸ Furthermore, the asymmetry of RNA reflecting more infectiousness nearer to the time of exposure, means that the sensitivity of the ideal test of infectiousness when measured against PCR may vary across the epidemic curve, from as high as 50–60% when an outbreak is surging to 20–30% or less as infections decline.¹⁹

LFT and the UK testing programme have been criticised^{1–3,5} for poor sensitivity in people without symptoms. In our view, these criticisms misinterpreted data from the interim report on the pilot of community testing in Liverpool, UK.^{20,21} When paired LFT and PCR testing was done in Liverpool, the epidemic curve was declining.²⁰ At this point, a priori one should expect a public health test that is highly sensitive for detecting infectious virus to show low overall sensitivity relative to PCR in people without symptoms or known exposures.

Further confusion reigns over PCR cycle threshold (Ct) values, viral loads, and infectiousness. In the Liverpool

pilot, Innova LFT picked up 19 of 24 (79%) samples with Ct below 20 and ten of 11 (91%) samples with Ct below 18.²⁰ The 66% sensitivity in the Liverpool interim report²⁰ was based cautiously on Ct below or equal to 25 indicating viable virus. For the laboratory processing of the Liverpool samples, Ct values of 21–18 most likely reflect the 100 000 to 1 million RNA copies per mL, quantities below which virus cultures usually become negative and transmission risks are low.^{22–24} Other laboratories place this threshold at a Ct of 30.²⁴ There is no international standardisation between laboratories and assays, leaving Ct calibration with viral load poorly reported and easy to misunderstand.

Early findings, widely reported,³ from a study by Ferguson and colleagues,²⁵ suggested that LFT had only 3% sensitivity for detecting SARS-CoV-2 among PCR-positive students at Birmingham University. Test underperformance was implied to explain finding only two positive results among 7189 individuals tested with Innova LFT.²⁵ In that study,²⁵ in a random sample of 710 (10%) LFT-negative individuals there were six PCR-positive results. That finding was extrapolated to 60 cases in the whole cohort, giving an extrapolated sensitivity of two of 62 (3.2%). The Ct values from the six PCR-positive samples were projected to Ct values for the 60 cases (54 unobserved plus six observed); in all six observed cases, viral loads were very low (Ct \geq 29 reflecting around <1000 RNA copies per mL in the laboratory used)—when LFT should be negative. By comparison, the Liverpool pilot saw virus levels 1000 to 1 million times higher.²⁰ In our view, the Birmingham study showed that PCR-positive asymptomatic students at a time of falling COVID-19 incidence had low viral loads compared with symptomatic members of the public attending testing centres and that LFT was working as expected.²⁶

We wholeheartedly support healthy scientific debate to inform policies promptly. The COVID-19 road ahead looks challenging; therefore, we need big, bold actions across science and society, such as the Liverpool community testing pilot. The prompt evidence from such pilots can inform policies and help maintain public confidence in the public health responses needed to navigate this pandemic's onward path.

IEB, MG-F, and MGS received grant funding from the UK Department of Health and Social Care to evaluate LFT in the Liverpool pilot that is discussed in this Comment. IEB reports fees from AstraZeneca as chief data scientist adviser via Liverpool University and a senior investigator grant from the National Institute

for Health Research (NIHR) outside the submitted work. MGS is Chair of the Infectious Disease Scientific Advisory Board and a minority shareholder in Integrum Scientific LLC, Greensboro, NC, USA, a company that has interests in COVID-19 testing but not with lateral flow technology, and reports grants from the NIHR, the Medical Research Council, and the Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool. MJM reports research funding by the US National Institutes of Health Director's Early Independence Award DP5-OD028145 and from Open Philanthropy and Good Ventures. TEP is supported by the NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at Oxford University in partnership with Public Health England (PHE), the NIHR Biomedical Research Centre, Oxford, and worked with PHE Porton on validation of LFT.

Michael J Mina, Tim E Peto, Marta García-Fiñana, Malcolm G Semple, *Iain E Buchan
buchan@liverpool.ac.uk

Center for Communicable Disease Dynamics, Department of Epidemiology and Department of Immunology and Infectious Diseases, Harvard T H Chan School of Public Health and Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA (MJM); Nuffield Department of Medicine, University of Oxford, Oxford, UK (TEP); Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK (MGS); Institute of Population Health, University of Liverpool, Liverpool L36 3GF, UK (MG-F, IEB)

- 1 Deeks J, Raffle A, Gill M. Covid-19: government must urgently rethink lateral flow test roll out. *BMJ Opinion*, Jan 12, 2021. <https://blogs.bmj.com/bmj/2021/01/12/covid-19-government-must-urgently-rethink-lateral-flow-test-roll-out> (accessed Feb 12, 2021).
- 2 Deeks J. Lateral flow tests cannot rule out SARS-CoV-2 infection. *BMJ* 2020; **371**: m4787.
- 3 Armstrong S. Covid-19: tests on students are highly inaccurate, early findings show. *BMJ* 2020; **371**: m4941.
- 4 Fearon E, Davis E, Stage H, et al. A response to "Covid-19: Controversial rapid test policy divides doctors and scientists". *BMJ* 2021; published online Jan 12. <https://doi.org/10.1136/bmj.n81>.
- 5 Kmietowicz Z. Covid-19: controversial rapid test policy divides doctors and scientists. *BMJ* 2021; published online Jan 12. <https://doi.org/10.1136/bmj.n81>.
- 6 van Kampen JJA, van de Vijver DAMC, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021; **12**: 267.
- 7 Cevik M, Tate M, Lloyd O, et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *Lancet Microbe* 2021; **2**: e13-22.
- 8 Jefferson T, Spencer EA, Brassej J, Heneghan C. Viral cultures for COVID-19 infectious potential assessment—a systematic review. *Clin Infect Dis* 2020; published online Dec 3. <https://doi.org/10.1093/cid/ciaa1764>.
- 9 WHO. Criteria for releasing COVID-19 patients from isolation: scientific brief. 2020. <https://www.who.int/news-room/commentaries/detail/criteria-for-releasing-covid-19-patients-from-isolation> (accessed Feb 12, 2021).
- 10 Sun J, Xiao J, Sun R, et al. Prolonged persistence of SARS-CoV-2 RNA in body fluids. *Emerg Infect Dis* 2020; **26**: 1834-38.
- 11 Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clin Infect Dis* 2020; published online May 22. <https://doi.org/10.1093/cid/ciaa638>.
- 12 Eyre DW, Lumley SF, O'Donnell D, et al. Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective observational study. *Elife* 2020; **9**: e60675.
- 13 Basile K, McPhie K, Carter I, et al. Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19. *Clin Infect Dis* 2020; published online Oct 24. <https://doi.org/10.1093/cid/ciaa1579>.
- 14 Huang CG, Lee KM, Hsiao MJ, et al. Culture-based virus isolation to evaluate potential infectivity of clinical specimens tested for COVID-19. *J Clin Microbiol* 2020; **58**: e01068-20.
- 15 Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020; **581**: 465-69.
- 16 Cevik M, Marcus JL, Buckee C, Smith TC. SARS-CoV-2 transmission dynamics should inform policy. *Clin Infect Dis* 2020; published online Sept 23. <https://doi.org/10.1093/cid/ciaa1442>.
- 17 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2. *BMJ* 2020; **371**: m3862.
- 18 Cleary B, Hay JA, Blumenstiel B, et al. Using viral load and epidemic dynamics to optimize 2 pooled testing in resource constrained settings. *medRxiv* 2021; published online Jan 15. <https://doi.org/10.1101/2020.05.01.20086801> (preprint).
- 19 Hay J, Kennedy-Shaffer L, Kanjilal S, Lipsitch M, Mina M. Estimating epidemiologic dynamics from single cross-sectional viral load distributions. *medRxiv* 2020; published online Oct 13. <https://doi.org/10.1101/2020.10.08.20204222> (preprint).
- 20 University of Liverpool. Buchan I, ed. Liverpool Covid-19 Community Testing Pilot interim report. University of Liverpool. 2020. <https://www.liverpool.ac.uk/media/livacuk/coronavirus/Liverpool,Community,Testing,Pilot,Interim,Evaluation.pdf> (accessed Feb 12, 2021).
- 21 Ashton M, Beale R, Buchan I, et al. Response to: Deeks et al. Briefing note for journalists on harm from continued rollout of the Innova Lateral Flow Test. University of Liverpool. Jan 22, 2021. <https://news.liverpool.ac.uk/2021/01/22/covid-19-liverpool-experts-challenge-flawed-reports-on-lateral-flow-tests/> (accessed Feb 12, 2021).
- 22 Lee L, Rozmanowski S, Pang M, et al. An observational study of SARS-CoV-2 infectivity by viral load and 2 demographic factors and the utility lateral flow devices to prevent 3 transmission. University of Oxford, 2021. http://modmedmicro.nsms.ox.ac.uk/wp-content/uploads/2021/01/infectivity_manuscript_20210119_merged.pdf (accessed Feb 12, 2021).
- 23 Marks M, Millat-Martinez P, Ouchi D, et al. Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study. *Lancet Infect Dis* 2021; published online Feb 2. [https://doi.org/10.1016/S1473-3099\(20\)30985-3](https://doi.org/10.1016/S1473-3099(20)30985-3).
- 24 Pray IW, Ford L, Cole D, et al. Performance of an antigen-based test for asymptomatic and symptomatic SARS-CoV-2 testing at two university campuses—Wisconsin, September–October 2020. *MMWR Morb Mortal Wkly Rep* 2021; **69**: 1642-47.
- 25 Ferguson J, Dunn S, Best A, et al. Validation testing to determine the effectiveness of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings. *medRxiv* 2020; published online Dec 24. <https://doi.org/10.1101/2020.12.01.20237784> (preprint).
- 26 Crozier A, Rajan S, Buchan I, McKee M. Put to the test: use of rapid testing technologies for covid-19. *BMJ* 2021; **372**: n208.

Reimagining India's health system: a Lancet Citizens' Commission



The COVID-19 pandemic and response are having profound impacts on India's people, leading to myriad health-care challenges, a looming economic recession, and humanitarian crises.¹ The long-standing need for universal health coverage (UHC) in India has been brought into sharp focus by the pandemic. The mission

of the Lancet Citizens' Commission on reimagining India's health system is to lay out the path to achieving UHC in India in the coming decade.

A guiding principle for this Commission is that structural change towards UHC can only be attained through consultative and participatory engagement

Published Online
December 10, 2020
[https://doi.org/10.1016/S0140-6736\(20\)32174-7](https://doi.org/10.1016/S0140-6736(20)32174-7)